<ul>
<li>分析师表示这两家中型生物科技公司具有两倍潜力</li>
</ul>
<p>Denali Therapeutics Inc.（纳斯达克：DNLI - 免费报告）- B. Riley 的股票分析师在 8 月 13 日星期三发布的报告中下调了对 Denali Therapeutics 2029 财年每股收益的预期。B. Riley 分析师 M. Mamtani 现在预计该公司将发布每股收益 0.19 美元，低于之前的 0.27 美元。Denali Therapeutics 当前全年的共识预期为每股（2.71 美元）。</p>
<p>其他一些股票研究分析师也对该股票发表了评论。Wedbush 将 Denali Therapeutics 的目标价从 32.00 美元下调至 30.00 美元，并在 5 月 7 日的报告中给予该公司 “跑赢大盘” 的评级。William Blair 在 4 月 24 日的报告中将 Denali Therapeutics 的评级上调至 “强力买入”。美国银行在 5 月 19 日的报告中将 Denali Therapeutics 的目标价从 28.00 美元下调至 27.00 美元，并给予该公司 “买入” 评级。HC Wainwright 在 5 月 7 日的报告中将 Denali Therapeutics 的目标价从 80.00 美元下调至 32.00 美元，并给予该公司 “买入” 评级。最后，Robert W. Baird 在 5 月 8 日的报告中将 Denali Therapeutics 的目标价从 30.00 美元下调至 29.00 美元，并给予该公司 “跑赢大盘” 评级。一位研究分析师对该股票给予持有评级，十三位分析师给予买入评级，三位分析师给予强力买入评级。根据 MarketBeat 的数据，该股票的共识评级为 “买入”，平均目标价为 33.85 美元。</p>
<p>获取 <strong>Denali Therapeutics</strong> 警报：</p>
<ul>
<li>3 家中型生物科技公司分析师认为可以翻倍</li>
</ul>
<p><strong>获取我们最新的 DNLI 股票报告</strong></p>
<h2>Denali Therapeutics 上涨 1.7%</h2>
<p>纳斯达克：DNLI 在周五的午盘交易中上涨 0.24 美元，达到 14.70 美元。该股票交易了 501,395 股，而其平均交易量为 1,409,008 股。该公司的 50 日移动平均线为 14.30 美元，200 日移动平均线为 15.42 美元。Denali Therapeutics 的 12 个月低点为 10.57 美元，12 个月高点为 33.33 美元。该公司的债务与股本比率为 0.01，速动比率为 9.56，流动比率为 10.27。该股票的市值为 21.5 亿美元，市盈率为-5.25，贝塔值为 1.36。</p>
<p>Denali Therapeutics（纳斯达克：DNLI - 获取免费报告）最近在 8 月 11 日星期一发布了季度财报。该公司报告本季度每股收益（0.72 美元），超出分析师共识预期的（0.74 美元）0.02 美元。在去年同期，该公司每股收益为（0.59 美元）。</p>
<h2>内部买卖</h2>
<p>在相关消息中，内部人士 Alexander O. Schuth 在 8 月 12 日星期二出售了 2,937 股该股票。股票以平均价格 13.58 美元出售，总价值为 39,884.46 美元。交易完成后，该内部人士直接持有 242,346 股公司股票，价值 3,291,058.68 美元。此交易代表其持股减少 1.20%。该出售在与证券交易委员会的法律文件中披露，相关信息可通过此超链接获取。此外，内部人士 Carole Ho 在 8 月 12 日星期二出售了 2,937 股该股票。股票以平均价格 13.58 美元出售，总交易额为 39,884.46 美元。交易完成后，该内部人士持有 217,391 股公司股票，价值约 2,952,169.78 美元。该交易使其持股减少 1.33%。该出售的披露信息可在此找到。内部人士在过去三个月内共出售了 501,962 股公司股票，价值 7,520,799 美元。12.50% 的股票由公司内部人士持有。</p>
<h2>机构资金流入和流出</h2>
<p>机构投资者最近调整了对该公司的持股。Envestnet Asset Management Inc.在第四季度将其在 Denali Therapeutics 的股份增加了 34.5%。Envestnet Asset Management Inc.现在持有 37,622 股公司股票，价值 767,000 美元，此前在上个季度购买了 9,643 股。Raymond James Financial Inc.在第四季度购买了 Denali Therapeutics 的新股份，价值约 533,000 美元。Sterling Capital Management LLC 在第四季度将其在 Denali Therapeutics 的股份增加了 589.9%。Sterling Capital Management LLC 现在持有 1,773 股公司股票，价值 36,000 美元，此前在上个季度购买了 1,516 股。巴克莱银行在第四季度将其在 Denali Therapeutics 的股份增加了 8.7%。巴克莱银行现在持有 278,067 股公司股票，价值 5,666,000 美元，此前在上个季度购买了 22,184 股。最后，XTX Topco Ltd 在第四季度购买了 Denali Therapeutics 的新股份，价值约 328,000 美元。92.92% 的股票目前由机构投资者持有。</p>
<h2>关于 Denali Therapeutics</h2>
<p>（获取免费报告）</p>
<p>Denali Therapeutics Inc 是一家生物制药公司，开发了一系列产品候选药物，旨在跨越血脑屏障，用于美国的神经退行性疾病和溶酶体储存疾病。该公司的运输载体（TV）支持的项目包括 DNL310 ETV，这是针对 MPS II 的 IDS 酶替代疗法项目；TAK-594/DNL593 目前处于前额叶痴呆 - 颗粒素的 1/II 期；DNL126 项目针对 MPS IIIA；DNL622 针对 MPS I，以及其他针对淀粉样β和 HER2 的临床前项目。</p>
<h2>特色文章</h2>
<ul>
<li>我们更看好的五只股票，胜过 Denali Therapeutics</li>
<li>投资者需要了解的击败市场的信息</li>
<li>应用材料公司的短期抛售是你买入的信号</li>
<li>便士股票适合你的投资组合吗？</li>
<li>Arista Networks：作为 AI 流量的收费站而获利</li>
<li>一些最佳的大盘股有哪些？</li>
<li>Elbit Systems 因创纪录的收益和 16 亿美元的合同而上涨</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsEstimatesChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9RE5MSQ?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsEstimatesChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9RE5MSQ"/></p>
<p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快和最准确的报道。此故事在发布前已由 MarketBeat 的编辑团队审核。请将任何问题或意见发送至 contact@marketbeat.com.</em></p>
<h2>你现在应该投资 1,000 美元在 Denali Therapeutics 吗？</h2>
<p>在你考虑 Denali Therapeutics 之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄向客户推荐的股票，建议在更广泛的市场注意到之前买入……而 Denali Therapeutics 并不在名单上。</p>
<p>虽然 Denali Therapeutics 目前在分析师中获得了买入评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>在这里查看这五只股票</p>

DNLI

<p>B. Riley 分析师将 Denali Therapeutics (NASDAQ:DNLI) 的 2029 财年每股收益预期从 $0.27 下调至 $0.19。该公司当前全年的共识收益预期为每股 ($2.71)。多位分析师已调整了他们的目标价，其中 Wedbush 将目标价从 $32.00 下调至 $30.00，而 William Blair 则将该股票评级上调至 “强力买入”。Denali 的股票目前交易价格为 $14.70，市值为 21.5 亿美元，市盈率为 -5.25。最近也有内部人士出售股票的报道</p>

<ul>
<li>Analysts Say These 2 Mid-Cap Biotechs Have 2x Potential</li>
</ul>
<div class="lb-trans"><ul>
<li>分析师表示这两家中型生物科技公司具有两倍潜力</li>
</ul>
</div><p>Denali Therapeutics Inc. (NASDAQ:DNLI - Free Report) - Stock analysts at B. Riley lowered their FY2029 EPS estimates for shares of Denali Therapeutics in a report issued on Wednesday, August 13th. B. Riley analyst M. Mamtani now expects that the company will post earnings of $0.19 per share for the year, down from their prior estimate of $0.27. The consensus estimate for Denali Therapeutics' current full-year earnings is ($2.71) per share.</p>
<div class="lb-trans"><p>Denali Therapeutics Inc.（纳斯达克：DNLI - 免费报告）- B. Riley 的股票分析师在 8 月 13 日星期三发布的报告中下调了对 Denali Therapeutics 2029 财年每股收益的预期。B. Riley 分析师 M. Mamtani 现在预计该公司将发布每股收益 0.19 美元，低于之前的 0.27 美元。Denali Therapeutics 当前全年的共识预期为每股（2.71 美元）。</p>
</div><p>A number of other equities research analysts have also commented on the stock. Wedbush lowered their price target on shares of Denali Therapeutics from $32.00 to $30.00 and set an &#34;outperform&#34; rating for the company in a report on Wednesday, May 7th. William Blair upgraded shares of Denali Therapeutics to a &#34;strong-buy&#34; rating in a report on Thursday, April 24th. Bank of America lowered their price target on shares of Denali Therapeutics from $28.00 to $27.00 and set a &#34;buy&#34; rating for the company in a report on Monday, May 19th. HC Wainwright lowered their price target on shares of Denali Therapeutics from $80.00 to $32.00 and set a &#34;buy&#34; rating for the company in a report on Wednesday, May 7th. Finally, Robert W. Baird decreased their price objective on shares of Denali Therapeutics from $30.00 to $29.00 and set an &#34;outperform&#34; rating for the company in a report on Thursday, May 8th. One research analyst has rated the stock with a hold rating, thirteen have issued a buy rating and three have issued a strong buy rating to the company. According to data from MarketBeat, the stock has a consensus rating of &#34;Buy&#34; and an average target price of $33.85.</p>
<div class="lb-trans"><p>其他一些股票研究分析师也对该股票发表了评论。Wedbush 将 Denali Therapeutics 的目标价从 32.00 美元下调至 30.00 美元，并在 5 月 7 日的报告中给予该公司 “跑赢大盘” 的评级。William Blair 在 4 月 24 日的报告中将 Denali Therapeutics 的评级上调至 “强力买入”。美国银行在 5 月 19 日的报告中将 Denali Therapeutics 的目标价从 28.00 美元下调至 27.00 美元，并给予该公司 “买入” 评级。HC Wainwright 在 5 月 7 日的报告中将 Denali Therapeutics 的目标价从 80.00 美元下调至 32.00 美元，并给予该公司 “买入” 评级。最后，Robert W. Baird 在 5 月 8 日的报告中将 Denali Therapeutics 的目标价从 30.00 美元下调至 29.00 美元，并给予该公司 “跑赢大盘” 评级。一位研究分析师对该股票给予持有评级，十三位分析师给予买入评级，三位分析师给予强力买入评级。根据 MarketBeat 的数据，该股票的共识评级为 “买入”，平均目标价为 33.85 美元。</p>
</div><p>Get <strong>Denali Therapeutics</strong> alerts:</p>
<div class="lb-trans"><p>获取 <strong>Denali Therapeutics</strong> 警报：</p>
</div><ul>
<li>3 Mid-Cap Biotechs Analysts Think Can Double</li>
</ul>
<div class="lb-trans"><ul>
<li>3 家中型生物科技公司分析师认为可以翻倍</li>
</ul>
</div><p><strong>Get Our Latest Stock Report on DNLI</strong></p>
<div class="lb-trans"><p><strong>获取我们最新的 DNLI 股票报告</strong></p>
</div><h2>Denali Therapeutics Trading Up 1.7%</h2>
<div class="lb-trans"><h2>Denali Therapeutics 上涨 1.7%</h2>
</div><p>NASDAQ:DNLI traded up $0.24 during midday trading on Friday, reaching $14.70. 501,395 shares of the stock traded hands, compared to its average volume of 1,409,008. The company has a fifty day moving average of $14.30 and a 200 day moving average of $15.42. Denali Therapeutics has a 12 month low of $10.57 and a 12 month high of $33.33. The company has a debt-to-equity ratio of 0.01, a quick ratio of 9.56 and a current ratio of 10.27. The stock has a market capitalization of $2.15 billion, a P/E ratio of -5.25 and a beta of 1.36.</p>
<div class="lb-trans"><p>纳斯达克：DNLI 在周五的午盘交易中上涨 0.24 美元，达到 14.70 美元。该股票交易了 501,395 股，而其平均交易量为 1,409,008 股。该公司的 50 日移动平均线为 14.30 美元，200 日移动平均线为 15.42 美元。Denali Therapeutics 的 12 个月低点为 10.57 美元，12 个月高点为 33.33 美元。该公司的债务与股本比率为 0.01，速动比率为 9.56，流动比率为 10.27。该股票的市值为 21.5 亿美元，市盈率为-5.25，贝塔值为 1.36。</p>
</div><p>Denali Therapeutics (NASDAQ:DNLI - Get Free Report) last posted its quarterly earnings results on Monday, August 11th. The company reported ($0.72) EPS for the quarter, beating analysts' consensus estimates of ($0.74) by $0.02. During the same quarter in the prior year, the business earned ($0.59) EPS.</p>
<div class="lb-trans"><p>Denali Therapeutics（纳斯达克：DNLI - 获取免费报告）最近在 8 月 11 日星期一发布了季度财报。该公司报告本季度每股收益（0.72 美元），超出分析师共识预期的（0.74 美元）0.02 美元。在去年同期，该公司每股收益为（0.59 美元）。</p>
</div><h2>Insider Buying and Selling</h2>
<div class="lb-trans"><h2>内部买卖</h2>
</div><p>In related news, insider Alexander O. Schuth sold 2,937 shares of the stock in a transaction dated Tuesday, August 12th. The shares were sold at an average price of $13.58, for a total value of $39,884.46. Following the completion of the transaction, the insider directly owned 242,346 shares in the company, valued at $3,291,058.68. This trade represents a 1.20% decrease in their position. The sale was disclosed in a legal filing with the Securities &amp; Exchange Commission, which is available through this hyperlink. Also, insider Carole Ho sold 2,937 shares of the stock in a transaction dated Tuesday, August 12th. The stock was sold at an average price of $13.58, for a total transaction of $39,884.46. Following the completion of the transaction, the insider owned 217,391 shares of the company's stock, valued at approximately $2,952,169.78. The trade was a 1.33% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 501,962 shares of company stock worth $7,520,799 in the last three months. 12.50% of the stock is owned by corporate insiders.</p>
<div class="lb-trans"><p>在相关消息中，内部人士 Alexander O. Schuth 在 8 月 12 日星期二出售了 2,937 股该股票。股票以平均价格 13.58 美元出售，总价值为 39,884.46 美元。交易完成后，该内部人士直接持有 242,346 股公司股票，价值 3,291,058.68 美元。此交易代表其持股减少 1.20%。该出售在与证券交易委员会的法律文件中披露，相关信息可通过此超链接获取。此外，内部人士 Carole Ho 在 8 月 12 日星期二出售了 2,937 股该股票。股票以平均价格 13.58 美元出售，总交易额为 39,884.46 美元。交易完成后，该内部人士持有 217,391 股公司股票，价值约 2,952,169.78 美元。该交易使其持股减少 1.33%。该出售的披露信息可在此找到。内部人士在过去三个月内共出售了 501,962 股公司股票，价值 7,520,799 美元。12.50% 的股票由公司内部人士持有。</p>
</div><h2>Institutional Inflows and Outflows</h2>
<div class="lb-trans"><h2>机构资金流入和流出</h2>
</div><p>Institutional investors have recently modified their holdings of the business. Envestnet Asset Management Inc. increased its stake in Denali Therapeutics by 34.5% during the 4th quarter. Envestnet Asset Management Inc. now owns 37,622 shares of the company's stock valued at $767,000 after purchasing an additional 9,643 shares in the last quarter. Raymond James Financial Inc. bought a new stake in Denali Therapeutics during the 4th quarter valued at about $533,000. Sterling Capital Management LLC increased its stake in Denali Therapeutics by 589.9% during the 4th quarter. Sterling Capital Management LLC now owns 1,773 shares of the company's stock valued at $36,000 after purchasing an additional 1,516 shares in the last quarter. Barclays PLC increased its stake in Denali Therapeutics by 8.7% during the 4th quarter. Barclays PLC now owns 278,067 shares of the company's stock valued at $5,666,000 after purchasing an additional 22,184 shares in the last quarter. Finally, XTX Topco Ltd bought a new stake in Denali Therapeutics during the 4th quarter valued at about $328,000. 92.92% of the stock is currently owned by institutional investors.</p>
<div class="lb-trans"><p>机构投资者最近调整了对该公司的持股。Envestnet Asset Management Inc.在第四季度将其在 Denali Therapeutics 的股份增加了 34.5%。Envestnet Asset Management Inc.现在持有 37,622 股公司股票，价值 767,000 美元，此前在上个季度购买了 9,643 股。Raymond James Financial Inc.在第四季度购买了 Denali Therapeutics 的新股份，价值约 533,000 美元。Sterling Capital Management LLC 在第四季度将其在 Denali Therapeutics 的股份增加了 589.9%。Sterling Capital Management LLC 现在持有 1,773 股公司股票，价值 36,000 美元，此前在上个季度购买了 1,516 股。巴克莱银行在第四季度将其在 Denali Therapeutics 的股份增加了 8.7%。巴克莱银行现在持有 278,067 股公司股票，价值 5,666,000 美元，此前在上个季度购买了 22,184 股。最后，XTX Topco Ltd 在第四季度购买了 Denali Therapeutics 的新股份，价值约 328,000 美元。92.92% 的股票目前由机构投资者持有。</p>
</div><h2>About Denali Therapeutics</h2>
<div class="lb-trans"><h2>关于 Denali Therapeutics</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（获取免费报告）</p>
</div><p>Denali Therapeutics Inc, a biopharmaceutical company, develops a portfolio of product candidates engineered to cross the blood-brain barrier for neurodegenerative diseases and lysosomal storage diseases in the United States. The company's transport vehicle (TV)-enabled programs include DNL310 ETV, an IDS enzyme replacement therapy program for MPS II; TAK-594/DNL593 which is in Phase 1/II for frontotemporal dementia-granulin; DNL126 program for MPS IIIA; and DNL622 for MPS I, as well as other preclinical programs that target amyloid beta and HER2.</p>
<div class="lb-trans"><p>Denali Therapeutics Inc 是一家生物制药公司，开发了一系列产品候选药物，旨在跨越血脑屏障，用于美国的神经退行性疾病和溶酶体储存疾病。该公司的运输载体（TV）支持的项目包括 DNL310 ETV，这是针对 MPS II 的 IDS 酶替代疗法项目；TAK-594/DNL593 目前处于前额叶痴呆 - 颗粒素的 1/II 期；DNL126 项目针对 MPS IIIA；DNL622 针对 MPS I，以及其他针对淀粉样β和 HER2 的临床前项目。</p>
</div><h2>Featured Articles</h2>
<div class="lb-trans"><h2>特色文章</h2>
</div><ul>
<li>Five stocks we like better than Denali Therapeutics</li>
<li>What Investors Need to Know to Beat the Market</li>
<li>Applied Materials' Knee-Jerk Sell-Off Is Your Signal to Buy</li>
<li>Are Penny Stocks a Good Fit for Your Portfolio?</li>
<li>Arista Networks: Cashing In as the Tollbooth for AI Traffic</li>
<li>What Are Some of the Best Large-Cap Stocks to Buy?</li>
<li>Elbit Systems Jumps on Record Earnings and a $1.6B Contract</li>
</ul>
<div class="lb-trans"><ul>
<li>我们更看好的五只股票，胜过 Denali Therapeutics</li>
<li>投资者需要了解的击败市场的信息</li>
<li>应用材料公司的短期抛售是你买入的信号</li>
<li>便士股票适合你的投资组合吗？</li>
<li>Arista Networks：作为 AI 流量的收费站而获利</li>
<li>一些最佳的大盘股有哪些？</li>
<li>Elbit Systems 因创纪录的收益和 16 亿美元的合同而上涨</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsEstimatesChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9RE5MSQ" alt="" original-src="https://www.marketbeat.com/scripts/EarningsEstimatesChart.ashx?Prefix=NASDAQ&amp;Symbol=DNLI"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快和最准确的报道。此故事在发布前已由 MarketBeat 的编辑团队审核。请将任何问题或意见发送至 contact@marketbeat.com.</em></p>
</div><h2>Should You Invest $1,000 in Denali Therapeutics Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 1,000 美元在 Denali Therapeutics 吗？</h2>
</div><p>Before you consider Denali Therapeutics, you'll want to hear this.</p>
<div class="lb-trans"><p>在你考虑 Denali Therapeutics 之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Denali Therapeutics wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄向客户推荐的股票，建议在更广泛的市场注意到之前买入……而 Denali Therapeutics 并不在名单上。</p>
</div><p>While Denali Therapeutics currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然 Denali Therapeutics 目前在分析师中获得了买入评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

股票分析师为 Denali Therap 2029 财年的收益设定了预期